Lentiviral Vector Design for Multiple shRNA Expression and Durable HIV-1 Inhibition

Human immunodeficiency virus type 1 (HIV-1) replication in T cells can be inhibited by RNA interference (RNAi) through short hairpin RNA (shRNA) expression from a lentiviral vector. However, for the development of a durable RNAi-based gene therapy against HIV-1, multiple shRNAs need to be expressed simultaneously in order to avoid viral escape. In this study, we tested a multiple shRNA expression strategy for different shRNAs using repeated promoters in a lentiviral vector. Although highly effective in co-transfection experiments, a markedly reduced activity of each expressed shRNA was observed in transduced cells. We found that this reduced activity was due to recombination of the expression cassette repeat sequences during the transduction of the lentiviral vector, which resulted in deletions of one or multiple cassettes. To avoid recombination, we tested different promoters for multiple shRNA expression. We compared the activity of the human polymerase III promoters U6, H1, and 7SK and the polymerase II U1 promoter. Activities of these promoters were similar, irrespective of which shRNA was expressed. We showed that these four expression cassettes can be combined in a single lentiviral vector without causing recombination. Moreover, whereas HIV-1 could escape from a single shRNA, we now show that HIV-1 escape can be prevented when four shRNAs are simultaneously expressed in a cell.

[1]  B. Berkhout,et al.  Lentiviral vectors that carry anti‐HIV shRNAs: problems and solutions , 2007, The journal of gene medicine.

[2]  A. Jetzt,et al.  Human Immunodeficiency Virus Type 1 Recombination: Rate, Fidelity, and Putative Hot Spots , 2002, Journal of Virology.

[3]  S. Barik,et al.  Inhibition of respiratory viruses by nasally administered siRNA , 2005, Nature Medicine.

[4]  Joshua N. Leonard,et al.  Computational Design of Antiviral RNA Interference Strategies That Resist Human Immunodeficiency Virus Escape , 2005, Journal of Virology.

[5]  B. Ramratnam,et al.  Promoter choice affects the potency of HIV-1 specific RNA interference. , 2003, Nucleic acids research.

[6]  B. Berkhout RNA interference as an antiviral approach: targeting HIV-1. , 2004, Current opinion in molecular therapeutics.

[7]  Ben Berkhout,et al.  HIV-1 can escape from RNA interference by evolving an alternative structure in its RNA genome , 2005, Nucleic acids research.

[8]  B. Berkhout,et al.  Design of extended short hairpin RNAs for HIV-1 inhibition , 2007, Nucleic Acids Research.

[9]  B. Berkhout,et al.  In vitro evolution of a highly replicating, doxycycline-dependent HIV for applications in vaccine studies , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[10]  R. Bernards,et al.  A System for Stable Expression of Short Interfering RNAs in Mammalian Cells , 2002, Science.

[11]  B. Berkhout,et al.  A novel approach for inhibition of HIV-1 by RNA interference: counteracting viral escape with a second generation of siRNAs , 2005, Journal of RNAi and gene silencing : an international journal of RNA and gene targeting research.

[12]  B. Palmer,et al.  Safety and Efficacy of a Lentiviral Vector Containing Three Anti-HIV Genes-CCR5 Ribozyme, Tat-rev siRNA, and TAR Decoy-in SCID-hu Mouse-Derived T Cells. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[13]  G. Nolan,et al.  Gene therapy progress and prospects: Novel gene therapy approaches for AIDS , 2005, Gene Therapy.

[14]  Anne Gatignol,et al.  Combinatorial delivery of small interfering RNAs reduces RNAi efficacy by selective incorporation into RISC , 2007, Nucleic acids research.

[15]  B. Scholte,et al.  Simultaneous targeting of HCV replication and viral binding with a single lentiviral vector containing multiple RNA interference expression cassettes. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[16]  Wulin Teo,et al.  An Essential Role for LEDGF/p75 in HIV Integration , 2006, Science.

[17]  Ben Berkhout,et al.  Silencing of HIV-1 with RNA interference: a multiple shRNA approach. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[18]  A. Kingsman,et al.  A Rev-Independent Human Immunodeficiency Virus Type 1 (HIV-1)-Based Vector That Exploits a Codon-Optimized HIV-1gag-pol Gene , 2000, Journal of virology.

[19]  W. An,et al.  Frequency of direct repeat deletion in a human immunodeficiency virus type 1 vector during reverse transcription in human cells. , 2001, Virology.

[20]  T. Morio,et al.  Hematopoietic stem cell–engrafted NOD/SCID/IL2Rγnull mice develop human lymphoid systems and induce long-lasting HIV-1 infection with specific humoral immune responses , 2007 .

[21]  Milton C Weinstein,et al.  The Lifetime Cost of Current Human Immunodeficiency Virus Care in the United States , 2006, Medical care.

[22]  B. Blom,et al.  Monitoring the effect of gene silencing by RNA interference in human CD34+ cells injected into newborn RAG2-/- gammac-/- mice: functional inactivation of p53 in developing T cells. , 2004, Blood.

[23]  S. Deeks Antiretroviral treatment of HIV infected adults , 2006, BMJ : British Medical Journal.

[24]  J. Seppen,et al.  Lentiviral vectors for efficient transduction of isolated primary quiescent hepatocytes. , 2002, Journal of hepatology.

[25]  B. Berkhout,et al.  The virion-associated incoming HIV-1 RNA genome is not targeted by RNA interference , 2006, Retrovirology.

[26]  B. Palmer,et al.  HIV-1 infection and CD4 T cell depletion in the humanized Rag2-/-γc-/- (RAG-hu) mouse model , 2006, Retrovirology.

[27]  B. Sandrock,et al.  RNA interference by small hairpin RNAs synthesised under control of the human 7S K RNA promoter , 2004, Biological chemistry.

[28]  I. Bozzoni,et al.  A new vector, based on the PolII promoter of the U1 snRNA gene, for the expression of siRNAs in mammalian cells. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[29]  J. Inoue,et al.  Lentivirus vectors expressing short hairpin RNAs against the U3-overlapping region of HIV nef inhibit HIV replication and infectivity in primary macrophages. , 2006, Blood.

[30]  A. Jetzt,et al.  High Rate of Recombination throughout the Human Immunodeficiency Virus Type 1 Genome , 2000, Journal of Virology.

[31]  B. Berkhout,et al.  Inhibition of human immunodeficiency virus type 1 by RNA interference using long-hairpin RNA , 2006, Gene Therapy.

[32]  B. Ramratnam,et al.  Human Immunodeficiency Virus Type 1 Escape from RNA Interference , 2003, Journal of Virology.

[33]  L. Greensmith,et al.  Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model , 2005, Nature Medicine.

[34]  B. Berkhout,et al.  The interplay between virus infection and the cellular RNA interference machinery , 2006, FEBS Letters.

[35]  Ben Berkhout,et al.  Human Immunodeficiency Virus Type 1 Escapes from RNA Interference-Mediated Inhibition , 2004, Journal of Virology.

[36]  T. Morio,et al.  Hematopoietic stem cell-engrafted NOD/SCID/IL2Rgamma null mice develop human lymphoid systems and induce long-lasting HIV-1 infection with specific humoral immune responses. , 2007, Blood.

[37]  M. Kay,et al.  Combinatorial RNAi: A Winning Strategy for the Race Against Evolving Targets? , 2007, Molecular Therapy.

[38]  Stacy L DeRuiter,et al.  RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[39]  J. Rossi,et al.  Novel Pol II Fusion Promoter Directs Human Immunodeficiency Virus Type 1-Inducible Coexpression of a Short Hairpin RNA and Protein , 2006, Journal of Virology.

[40]  B. Harder,et al.  Lentivirus vectors encoding both central polypurine tract and posttranscriptional regulatory element provide enhanced transduction and transgene expression. , 2001, Human gene therapy.

[41]  R. Surabhi,et al.  RNA Interference Directed against Viral and Cellular Targets Inhibits Human Immunodeficiency Virus Type 1 Replication , 2002, Journal of Virology.

[42]  H. Paulson,et al.  RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[43]  B. Nuttin,et al.  Lentiviral vector-mediated delivery of short hairpin RNA results in persistent knockdown of gene expression in mouse brain. , 2003, Human gene therapy.

[44]  H. Spits,et al.  Experimental Models to Study Development and Function of the Human Immune System In Vivo , 2006, The Journal of Immunology.

[45]  John J Rossi,et al.  Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR5 ribozyme, and a nucleolar-localizing TAR decoy. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[46]  J. Rossi,et al.  Inhibition of HIV-1 infection by lentiviral vectors expressing Pol III-promoted anti-HIV RNAs. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[47]  M. Emerman,et al.  Changes in growth properties on passage in tissue culture of viruses derived from infectious molecular clones of HIV-1LAI, HIV-1MAL, and HIV-1ELI. , 1991, Virology.

[48]  John R. Mascola,et al.  Gene transfer in humans using a conditionally replicating lentiviral vector , 2006, Proceedings of the National Academy of Sciences.

[49]  J. Rossi,et al.  Current status of gene therapy strategies to treat HIV/AIDS. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[50]  M. Kumar,et al.  Systematic determination of the packaging limit of lentiviral vectors. , 2001, Human gene therapy.

[51]  Yingchun Lu,et al.  Poly(U) and polyadenylation termination signals are interchangeable for terminating the expression of shRNA from a pol II promoter. , 2004, Biochemical and biophysical research communications.

[52]  R. Akkina,et al.  HIV-1 resistance conferred by siRNA cosuppression of CXCR4 and CCR5 coreceptors by a bispecific lentiviral vector , 2005, AIDS research and therapy.